Saturday, October 24, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· November 24, 2025

Nanox.AI Bone Solutions, Advanced AI-Powered Software for Spine Assessment, Recommended by NICE for Early Value Assessment in UK National Health Service hospitals

View original at globenewswire.com
Nanox.AI Bone Solutions, Advanced AI-Powered Software for Spine Assessment, Recommended by NICE for Early Value Assessment in UK National Health Service hospitals Nanox’s HealthOST and HeathVCF recommended for use in UK National Health Service hospitals for a three-year period as the use of AI solutions in bone disease…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • NICE has recognized the potential of these tools through the Early Value Assessment, enabling us to generate the evidence needed to bring earlier detection to many more patients

    80% confidence
  • AI technologies can help healthcare professionals spot VFFs on X-ray images and CT scans involving the spine, that are done for unrelated conditions (opportunistic detection). This could help identify more people with a vertebral fragility fracture who need treatment to improve their quality of life and reduce the risk of future fractures.

    80% confidence
  • Nanox.AI's bone solutions represent a major step forward in transforming how we detect vertebral fragility fractures and intervene earlier in osteoporosis. The ADOPT trial has shown the impact of proactive identification, and these AI tools can help bring that approach into routine NHS care.

    80% confidence
  • Inclusion in this Early Value Assessment by NICE provides clear initial validation of the benefit that our AI bone solutions can provide in detection of vertebral fragility fractures, something which many solutions providers have yet to demonstrate. Our inclusion reflects that Nanox.AI delivers clinically validated, real-world results, not just theoretical concepts.

    80% confidence
  • By detecting low bone mineral density early—before symptoms appear—Nanox.AI solutions can be truly life-changing for patients who might otherwise remain undiagnosed

    80% confidence
  • Two of the five bone solutions recommended by NICE are from Nanox AI, enabling the company to build a footprint in UK hospitals

    80% confidence
  • HealthOST and HealthVCF analyze existing CT scans and require no additional imaging, introduce no extra radiation exposure and impose no added burden on the patient, positioning them as highly cost-effective methods to help identify risk earlier

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise Software Races to Govern and Consolidate Around Agentic AI
Enterprise software vendors are repositioning around autonomous AI agents. Salesforce is acquiring Braze, ServiceNow is launching agent governance tools (AI Passport, Super Intelligence Control Tower), SAP is pushing its 'Autonomous Enterprise', and Zeta is launching AthenaOS and its own inference model. Palantir is embedding itself in banking, aviation and sovereign AI infrastructure through partnerships with Customers Bank, Surf Air, Ondas and Armada. Governance, data sovereignty and enforced policy are emerging as preconditions for regulated sectors like finance. Investors such as Norwest see room to disrupt ERP and finance software, and they caution that AI should not be trusted with financial calculations. Consolidation and shareholder disputes (Salesforce/Braze, Tiny/Oso Cloud, ZenaTech/Boardwalktech) show the market reshaping.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,484 source documents archived
Query this data → isubstrate.com